Altitude Sickness Drug Appears to Slow Progression of Glioblastoma
Acetazolamide increased sensitivity to treatment and enhanced survival in mice
A drug used to treat altitude sickness — as well as glaucoma, epilepsy, heart failure and seizures — may also offer significant gains for patients with a fast-growing brain tumor known as glioblastoma, according to a study.
The drug, acetazolamide, sold under the trade name Diamox, is “cheap to make, easy to take and has limited side effects,” said study director Bahktiar Yamini, MD, a professor of neurosurgery at the University of Chicago Medicine.
“I take it myself, whenever I go to the Rocky Mountains,” he said, “two pills a day.” The most common side effect of Diamox is “a metallic taste when drinking something carbonated.”
The most frequently used chemotherapy for gliomas is a drug called temozolomide (TMZ). However, not all patients respond to this drug. Median survival with this disease is about 14 months.
Click here to read more.
INS 14th World Congress
May 25-30, 2019; Sydney
12th Annual Cervical Spine Research Society Hands-on Cadaver Course
May 30-June 1, 2019; St. Louis
Brain Tumor Biotech Summit
June 7, 2019; New York
Minimally Invasive Cranial Neurosurgery: Recent Technical Advances With Hands-On Laboratory
June 7-8, 2019; New York
The 25th Annual Meeting of the Organization for Human Brain Mapping (OHBM 2019)
June 9-13, 2019; Rome